• Investors
  • News
  • Subscribe
Hit enter to search or ESC to close
Cardax, Inc. | CDXI
  • About Us
    • Corporate Overview
    • Corporate Presentation
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Lead Scientific Team
    • Company History
  • Astaxanthin
    • Overview
      • Astaxanthin Overview
      • History and Background
      • Safety
      • Mechanism of Action
      • Synthetic vs. Natural Astaxanthin
    • Research in Key Addressable Markets
      • Cardiovascular Disease
      • Metabolic Disease
      • Liver Disease
      • Arthritis
      • Aging
      • Coronavirus Disease 2019 (COVID-19)
    • Scientific Literature
  • Programs
    • Product Platform
    • Commercialization Strategy
    • CDX-101
    • CDX-301
    • ZanthoSyn®
    • CHASE Clinical Trial
    • Intellectual Property
  • Newsroom
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact Us
Cardax, Inc. | CDXI

Press Releases

Investor Relations
Investors
  • Overview
  • News / Events
    • Press Releases
    • Media Coverage
    • IR Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Profile
    • Management Team
    • Contacts
    • FAQ
  • Financial Info
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed

Cardax Reports Q1 2019 Results

May 17, 2019

Cardax Reports 2018 Results

Mar 28, 2019

Cardax to Present at NobleCon XV

Jan 25, 2019

Cardax and GNC Announce Expanded ZanthoSyn® Sales and Marketing Program

Dec 3, 2018

Cardax Names Former Amarin Head of Development Paresh N. Soni, MD, PhD, to lead Clinical and Regulatory Strategy

Nov 28, 2018

Cardax Reports Q3 2018 Results

Nov 13, 2018

Cardax Launches Human Clinical Trial Targeting Cardiovascular Inflammatory Health

Oct 2, 2018

Cardax Reports Q2 2018 Results

Aug 13, 2018

Cardax Announces Successful Completion of Warrant Exchange Offer

Jul 30, 2018

Cardax Announces Extension of Warrant Exchange Offer to July 27, 2018

Jul 23, 2018
RSS
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8

    News / Events

    • Press Releases
    • Media Coverage
    • IR Calendar
    • Presentations
    • Email Alerts
    Subscribe to Receive Updates by E-Mail Cardax News Alerts

    Recent News

    • Cardax Reports Q3 2020 ResultsNovember 13, 2020
    • Cardax Reports Q2 2020 ResultsAugust 14, 2020

    © 2021 Cardax, Inc. | Disclaimer and Terms of Use

    • About Us
      • Corporate Overview
      • Corporate Presentation
      • Management Team
      • Board of Directors
      • Scientific Advisory Board
      • Lead Scientific Team
      • Company History
    • Astaxanthin
      • Overview
        • Astaxanthin Overview
        • History and Background
        • Safety
        • Mechanism of Action
        • Synthetic vs. Natural Astaxanthin
      • Research in Key Addressable Markets
      • Scientific Literature
    • Programs
      • Product Platform
      • Commercialization Strategy
      • CDX-101
      • CDX-301
      • ZanthoSyn®
      • CHASE Clinical Trial
      • Intellectual Property
    • Newsroom
    • Investors
      • Investor Overview
      • News / Events
      • Company Information
      • Financial Information
      • Stock Information
      • SEC Filings
      • Corporate Governance
    • Contact Us
    • Investors
    • News
    • Subscribe